Advertisement

Wrapping Drug Combinations for Therapeutic Editing of Side Effects: Systems Biology Meets Wrapping Technology

  • Ariel Fernández Stigliano
Chapter

Abstract

Wrapping designs have limitations arising from similarities in the biomolecular interfaces of on-target and off-target homologous proteins and also from the highly diverse cellular contexts wherein a protein may constitute a desirable or undesirable target. While dehydron wrapping enables the control of specificity, it may not be able to exclude every single toxicity-related target, especially if the latter shares with the therapeutically relevant targets a similar dehydron pattern in the drug-binding region. In such circumstances, we may need to resort to a multicomponent therapy where one drug acts synergistically with the other while selectively antagonizing it in the specific cellular context where the action of the first drug promotes toxicity. This chapter explores these a-priori therapeutic possibilities. As previously described, due to their ability to interfere with signal transduction events controlling cell proliferation and fate, kinase inhibitors hold promise as anticancer agents. Nevertheless, the functional role of a kinase depends on the cellular context and hence kinase inhibition in an off-target cell may lead to undesired side effects. Motivated by these observations, we explore a mode of “therapeutic editing” where one drug—the editor—suppresses the side effect promoted by the primary drug as it impacts off-target cells. Editor and primary drug have overlapping therapeutic impact, while the editor suppresses the downstream propagation of toxicity-related signaling triggered by the primary drug in an off-target cellular context.

Keywords

Renal Cell Carcinoma Chronic Myeloid Leukemia Selectivity Filter Primary Drug Combination Drug Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Widakowich C, de Castro G, de Azambuja E, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12:1443–1455CrossRefPubMedGoogle Scholar
  2. 2.
    Schmidinger M, Zielinski CC, Vogl UM et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204–5212CrossRefPubMedGoogle Scholar
  3. 3.
    Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803–812CrossRefPubMedGoogle Scholar
  4. 4.
    Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475–485CrossRefPubMedGoogle Scholar
  5. 5.
    Force T, Krause D, van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332–344CrossRefPubMedGoogle Scholar
  6. 6.
    Force T, Kerkela R (2008) Cardiotoxicity of the new cancer therapeutics—mechanisms of, and approaches to, the problem. Drug Discov Today 13:778–784CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Kerkela R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–916CrossRefPubMedGoogle Scholar
  8. 8.
    Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitnib. Lancet 370:2011–2019CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Fernández A, Crespo A, Tiwari A (2009) Is there a case for selectively promiscuous anticancer drugs? Drug Discov Today 14:1–5CrossRefPubMedGoogle Scholar
  10. 10.
    Zhang X, Crespo A, Fernández A (2008) Turning promiscuous kinase inhibitors into safer drugs. Trends Biotech 26:295–301CrossRefGoogle Scholar
  11. 11.
    Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296–313CrossRefPubMedGoogle Scholar
  12. 12.
    Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782–1788CrossRefPubMedGoogle Scholar
  13. 13.
    Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G (2007) An anticancer c-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117:4044–4054CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Kitano H (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6:202–209CrossRefPubMedGoogle Scholar
  15. 15.
    Torchilin VP (2006) Multifunctional nanocarriers. Adv Drug Deliv Rev 58:1532–1555CrossRefGoogle Scholar
  16. 16.
    Langer R (2001) Drug delivery: drugs on target. Science 293:58–59CrossRefPubMedGoogle Scholar
  17. 17.
    Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818–1822CrossRefPubMedGoogle Scholar
  18. 18.
    Deninger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640–2653CrossRefGoogle Scholar
  19. 19.
    Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer drugs. Nat Rev Drug Discov 5:649–659CrossRefPubMedGoogle Scholar
  20. 20.
    Keith CT, Borisky AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4:71–78CrossRefPubMedGoogle Scholar
  21. 21.
    Zimmermann GR, Lehar J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12:34–42CrossRefPubMedGoogle Scholar
  22. 22.
    Verweij J, Casali P, Kotasek D et al (2007) Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 43:974–978CrossRefPubMedGoogle Scholar
  23. 23.
    Atallah E, Durand JB, Kantarjian H, Cortes J (2007) Congestive heart failure is a rare event in patients receiving imatinib. Blood 110:1233–1237CrossRefPubMedGoogle Scholar
  24. 24.
    Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134CrossRefPubMedGoogle Scholar
  25. 25.
    O’Neill E, Rushworth L, Baccarini M, Kolch W (2004) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product raf-1. Science 306:2267–2270CrossRefPubMedGoogle Scholar
  26. 26.
    Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290CrossRefPubMedGoogle Scholar
  27. 27.
    Chen J, Zhang X, Fernández A (2007) Molecular basis for specificity in the druggable kinome: sequence-based analysis. Bioinformatics 23:563–572CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734–745CrossRefPubMedGoogle Scholar
  29. 29.
    O’Neill EE, Matallanas D, Kolch W (2005) Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res 65:5485–5487CrossRefPubMedGoogle Scholar
  30. 30.
    Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotech 26:127–132CrossRefGoogle Scholar
  31. 31.
    Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P (2006) Dasatinib. Nat Rev Drug Discov 5:717–718CrossRefPubMedGoogle Scholar
  32. 32.
    Fernández A, Sessel S (2009) Selective antagonism of anticancer drugs for side effect removal. Trends Pharmacol Sci 30:403–410CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.National Research Council–CONICETBuenos AiresArgentina
  2. 2.Former Karl F. Hasselmann Endowed Chair Professor of BioengineeringRice UniversityHoustonUSA

Personalised recommendations